BRINSUPRI: Insmed's Landmark Drug Redefining Non-Cystic Fibrosis Bronchiectasis Treatment
BRINSUPRI: Insmed's Landmark Drug Redefining Non-Cystic Fibrosis Bronchiectasis Treatment For decades, non-cystic fibrosis bronchiectasis (NCFB) patients had no dedicated, FDA-approved therapy — relying instead on antibiotics, airway clearance techniques, and supportive care to manage a chronic and often debilitating condition. That changed with the arrival of brinsupri (brensocatib),...
0 Comentários 0 Compartilhamentos 18 Visualizações 0 Anterior